Smith & Nephew reported better than expected Q1 22 sales, up 5.9% on an underlying basis, driven by broad-based momentum in sports medicine and ENT (+8.6%) and advanced wound management (+8%). Regionally, growth was led by emerging markets (+14.3%) supported by established markets (+4.1%).
The FY 22 outlook of 4-5% top-line growth and 50bps trading margin expansion was unchanged.
We will marginally upgrade our estimates to reflect the strong Q1 momentum.
28 Apr 2022
Strong Q1 22 as procedure volumes recover
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 22 as procedure volumes recover
Smith & Nephew plc (SN:LON) | 994 0 0.0% | Mkt Cap: 8,689m
- Published:
28 Apr 2022 -
Author:
Virendra Chauhan -
Pages:
3
Smith & Nephew reported better than expected Q1 22 sales, up 5.9% on an underlying basis, driven by broad-based momentum in sports medicine and ENT (+8.6%) and advanced wound management (+8%). Regionally, growth was led by emerging markets (+14.3%) supported by established markets (+4.1%).
The FY 22 outlook of 4-5% top-line growth and 50bps trading margin expansion was unchanged.
We will marginally upgrade our estimates to reflect the strong Q1 momentum.